Skip to content

Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot

Mixed-methods Process Evaluation of a Residence-Based SARS-CoV-2 Testing Participation Pilot on a UK University Campus During the COVID-19 Pandemic.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05045989
Acronym
RB-TPP
Enrollment
152
Registered
2021-09-16
Start date
2021-04-01
Completion date
2021-07-31
Last updated
2021-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid19

Brief summary

Mixed-methods process evaluation of a residence-based asymptomatic SARS-CoV-2 testing participation pilot

Detailed description

Regular testing for SARS Coronavirus 2 (SARS-CoV-2) is an important strategy for controlling virus outbreaks on university campuses during the COVID-19 pandemic but testing participation rates can be low. The Residence-Based Testing Participation Pilot (RB-TPP) was a novel intervention implemented at two student residences on a large university campus in the UK over four weeks. The aim of the pilot was to increase the frequency of asymptomatic SARS-CoV-2 saliva testing onsite. This process evaluation aimed to determine whether RB-TPP was implemented as planned and identify implementation barriers and facilitators. A mixed-methods process evaluation was conducted alongside the RB-TPP. Evaluation participants were students (who opted in, or out of the RB-TPP) and staff with a role in service provision or student support. Monitoring data were collected from the intervention delivery team and meeting records. Data were collected from students via an online survey (n=152) and seven focus groups (n=30), and from staff via individual interviews (n=13). Quantitative data were analysed descriptively and qualitative data thematically.

Interventions

BEHAVIORALResidence-based testing participation pilot (SARS-CoV-2 testing with relaxed social distancing restrictions)

SARS-CoV-2 asymptomatic saliva testing (as available to all students at staff at the participating university) delivered with relaxed social distancing (behavioural element) in two halls of residence.

Sponsors

University of Nottingham
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Masking description

N/A process evaluation, single group intervention

Intervention model description

Process evaluation of a SARS-CoV-2 testing participation uptake scheme in a single group of students living in two halls of residence.

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* Student is living in one of the two participating halls of residence. * staff with operational or student support role. * consents to participate.

Exclusion criteria

* Student is not living in the hall of residence at the start of the RB-TPP. * does not consent to participate.

Design outcomes

Primary

MeasureTime frameDescription
Reach1 weekProgram reach was evaluated through the number of students recruited into the RB-TPP compared to the number of potentially eligible students living in one of the two participating sites in April 2021

Secondary

MeasureTime frameDescription
Adherence4 weeksParticipant adherence was defined as the proportion of students who completed all tests offered.
Dose4 weeksNumber of tests offered
Generalised Anxiety Disorders Scale (Spitzer et al., 2006; Kroenke et al., 2007).4 weeksA 7-item anxiety scale with good reliability, as well as criterion, construct, factorial, and procedural validity. A cut point of \>=10 indicates moderate to severe anxiety. Higher scores indicate higher anxiety.
Student Focus Groups4 weeksStudent's views towards the RB-TPP. Small group discussions lasting approximately 60 mins conducted at mid-point and/or programme end.
Staff interviews4 weeksStaff views towards the RB-TPP. Individual interviews lasting approximately 20-60 mins conducted at programme end.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026